Clinical Trial

Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion

Enrolling by Invitation Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with Exparel vs with standard of care 0.25% Bupivacaine HCl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion. The investigators hypothesize that thoracolumbar interfascial plane block with Exparel will outperform standard of care (supplemented with interfascial plane block of 0.25% Bupivacaine HCl) with regards to pain reduction, narcotic use, length of hospital stay, time to mobilization with physical therapy, narcotic usage in the hospital, and post operative pain scores.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-03; most recent amendment 2025-02-24.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-06-12
Trial Details
NCT Number NCT06350981
Lead Sponsor Foundation for Orthopaedic Research and Education
Collaborators: Pacira Pharmaceuticals, Inc
Conditions Back Pain, Surgery-Complications, Narcotic Use, Physical Stress, Post Operative Pain
Enrollment 76 participants
Start Date 2024-04-30
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-25